Somerset Emsam "approvable
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Somerset receives "approvable" letter Jan. 30 for its transdermal selegiline patch, Emsam. The Mylan/Watson joint venture indicated that FDA is requesting additional pharmacology/toxicology studies as well as postmarketing pharmacokinetic and safety studies. Tyramine dietary restrictions in labeling are also requested. The sponsors resubmitted the Emsam NDA Aug. 1, 2003 for treatment of depression following a March 2002 "not approvable" letter (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 14)...
You may also be interested in...
Somerset Emsam NDA Resubmission Adds Long-Term Indication, Higher Doses
Somerset’s resubmitted NDA for the selegiline patch Emsam seeks an indication for relapse prevention as well as treatment of depression.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.